BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2007

View Archived Issues

Huya licenses ex-China rights to chidamide

Read More

GSK reviews 2006 progress, anticipates 2007 milestones

Read More

Exelixis updates EXEL-2819 profile

Read More

IRBM presents second-generation class I HDAC inhibitors at recent congress

Read More

GPI-1046 inhibits HIV-associated sensory neuropathy in vivo

Read More

NYVAC-C HIV vaccine assessed with and without DNA-C in healthy volunteers

Read More

T-cell increases seen in HIV-infected patients given recombinant interleukin-7

Read More

New treatment options for neurological disorders disclosed in recent patent literature

Read More

Novel factor Xa inhibitor described at GSK

Read More

Phase Ib/II data on single agent ADH-1 presented

Read More

Dyax and Glenmark to cooperate on discovery of therapeutic antibodies

Read More

NGX-267 studied in multiple-dose phase I trial

Read More

BioLineRx in-licenses novel drug delivery system

Read More

First human microdosing trial completes for I-3D compound

Read More

Novel treatment strategy for glaucoma and ocular hypertension claimed by Allergan

Read More

Novel therapeutic strategies for metabolic disorders described in recent patents

Read More

ObeCure begins phase II study for OBE-101 to prevent Zyprexa weight gain

Read More

Cell Therapeutics seeks SPA for pixantrone trial in indolent NHL

Read More

Enzo studies gene therapy for HIV-1 in phase I/II trial

Read More

IND filing for pivotal study of improved octreotide formulation

Read More

Allegra Oral Suspension now available for children

Read More

GTC grants expanded license to PharmAthene in support of Protexia

Read More

Virax grants Transgene access to Co-X-Gene technology

Read More

SPA agreement for phase III EOquin trials in noninvasive bladder cancer

Read More

Amitiza begins U.S. postmarking studies, Japanese phase I study

Read More

MEM-354 begins phase IIa study for Alzheimer's disease

Read More

CYT003-QbG10 significantly improves allergy symptoms in hay fever patients

Read More

Tyrima safe and well tolerated in phase I trial

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing